Newly Diagnosed Multiple Myeloma Recruiting Phase 3 Trials for Elotuzumab (DB06317)

IndicationStatusPhase
DBCOND0036257 (Newly Diagnosed Multiple Myeloma)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03948035Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMTreatment